Bionomics



# BIONOMICS NOW

## CEO Report

**Dear Shareholders,**

Welcome to the September Edition of Bionomics NOW. I am delighted to report the continuing progress of Bionomics on a number of fronts. Earlier this quarter we announced the completion of GMP (Good Manufacturing Process) synthesis for our anti-anxiety drug BNC210. In our July Bionomics NOW, I reported the initiation of the GMP manufacturing process by Sai Advantium. Together, these important milestones for our company mark progress towards reaching our goal of taking BNC210 to clinical trial next year. I look forward to sharing progressive updates with you as we move forward. In this edition, we expand upon BNC210 developments including the latest data presented in Barcelona, Spain.

Our clinical trial of anti-cancer compound BNC105 continues to make good progress with patient enrolment proceeding as planned and with some encouraging indications that we are on the right track.

Our preliminary final results for the year ended 30 June 2008 were released to the market on 22 August. We are in a very strong position with new partnerships and clinical developments.

Finally, let me say that Bionomics has a great team focused on its success. We have a number of important milestones ahead which will continue to define Bionomics as a rising star and I feel privileged to continue at the helm for a further three years.

Very shortly we will be making available our Annual Report and I look forward to sharing with you a further update on Bionomics. Thank you for your ongoing support. ●

**Dr Deborah Rathjen** Chief Executive Officer

## ECNP - New Data on BNC210 Presented

**Bionomics presented new data on BNC210 at the European College of Neuropsychopharmcology Congress (ECNP) in Barcelona confirming that BNC210 decreases anxiety in three animal models.** Additional BNC210 data presented indicated that BNC210 acts longer than Valium (diazepam), the most commonly prescribed anxiety drug. Furthermore, pre-clinical safety studies confirm the suitability of oral delivery of BNC210 and show that BNC210 is safe even at doses 10,000 times the minimum effective dose.

Dr. Sue O'Connor, the project leader for BNC210 said "we were pleased to be able to present our latest findings at such a high caliber scientific meeting". ●

**Would you like to receive your newsletter via email?**

If you would like to receive your eNewsletter please **email** investorrelations@bionomics.com.au

## Deborah Rathjen Extends Contract Until 7th August 2011


On the 8th of August, Bionomics announced the extension of the service of Dr. Deborah Rathjen, as CEO and Managing Director.

Dr. Peter Jonson, Chairman of Bionomics said:

"The Board is pleased to have extended Dr. Deborah Rathjen's contract, she is a respected member of our team and in the broader biotechnology and pharmaceutical community. She has successfully led Bionomics through a number of company changing events and achieved significant uplift in share value." ●

# GMP Synthesis of Anti-Anxiety Drug BNC210 Completed

In July, Bionomics announced that it had completed the GMP (Good Manufacturing Practice) synthesis of its anti-anxiety drug candidate BNC210. In order to complete a GMP synthesis, all manufacturing and testing of equipment must be qualified as suitable for use, and all operational methodologies and procedures utilized in the drug manufacturing process must demonstrate that they can perform their purported function.

Having now successfully achieved this milestone, Bionomics is focusing on the completion of safety and tolerability studies currently underway at WIL Laboratories in the US and the submission of regulatory filings necessary for approval to be given for clinical trials. ●

# Bionomics' 2007/2008 Preliminary Final Results

Bionomics announced on the 22nd August its preliminary financial results for the year ended 30 June 2008. In line with expectations Bionomics' cash position at 30 June 2008 was $6,280,480 with the loss recorded for the period being $4,783, 917. Receivables at 30 June 2008 were $2,314,931 which included the US$2 million upfront payment from Merck Serono which was subsequently received in July.

| | AT 30 JUNE 2008 |
|---|---|
| Cash position | $6,280,480 |
| Loss recorded | $4,783,917 |
| Receivables | $2,314,931 |
| Revenues | $5,256,963 (an increase of 272%) |
| Grant income | $1,825,165 |

Revenues for the period increased to $5,256,963 (an increase of 272%) as a result of the US$2 million upfront payment under the Merck Serono development and licensing deal signed in June and a US$1 million milestone payment under Bionomics' 2006 licensing agreement with Genmab A/S. Grant income for the period was $1,825,165. ●

For the full report, please send an email to investorrelations@bionomics.com.au with '2007/2008 financial report' in the subject line.

# Update on BNC105 Clinical Trial




The primary objective of the trial which began in February 2008 is to establish the safety profile of BNC105 and recommend dose levels for further evaluation in future trials.

Patients enrolled in the BNC105 trial are being evaluated for changes in the blood vessels of their solid tumours as well as changes in the overall tumour size. These investigations may provide preliminary evidence that the anti-tumour activity seen with BNC105 in animal models is also seen in human cancer patients. A number of biomarkers are also being evaluated in samples from treated patients to confirm the biological activity of BNC105.

The first patient was dosed at 2.1 mg/m², and as of August 2008, three dose levels had been evaluated and a fourth is in progress with a fifth anticipated to commence later in September. BNC105 has been well tolerated by patients receiving treatment with some preliminary signals of activity as measured by DCE-MRI/CT scan. A small number of patients have continued to receive BNC105 beyond 2 cycles of treatment.

Dr David Bibby, Director Drug Development said "The trial is running very well. We are several dose cohorts in at three sites, with a fourth clinical site to join the trial in Q3".

Planning for the next phase of the development of BNC105 has commenced and Bionomics has initiated discussions with several clinical investigators and sites both in Australia and the United States with the target of initiating Phase II trials of BNC105 in 2009. ●

## See Bionomics

**12-14 October 2008**
BioPartnering Europe
London, UK

**10-12 November 2008**
Rodman & Renshaw
10th Annual Healthcare Conference
New York, US

**1-2 December 2008**
CNS Partnering, Licensing & Dealmaking Summit
Boston, US

## Contact Bionomics

31 Dalgleish Street
Thebarton, SA 5031
Australia

Tel: +61 8 8354 6101

Deborah Rathjen
CEO & Managing Director

drathjen@bionomics.com.au

**Factors Affecting Future Performance** This publication contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this publication that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105 and BNC210, its drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this publication.